Cryoport Q2 2026 revenue $49.0M (+8% YoY); achieves positive adjusted EBITDA

Cryoport, Inc.

Revenue $49.0M, up 8% YoY; Life Sciences Services +15%, BioStorage/BioServices +25%.
Adjusted EBITDA from continuing operations positive $0.4M vs -$0.9M in Q2 2025.
Net loss attributable to common stockholders $0.20 per share (vs $2.13 income in Q2 2025, which included divestiture gain).
Supporting 779 clinical trials and 22 commercial CGT as of June 30, 2026.
Cash and short-term investments $396.7M; anticipate 11 possible BLA/MAA applications in H2 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.